

CP-547632 hydrochloride

Chemical Properties


CAS No. : 252003-71-7

Formula: C₂₀H₂₅BrClF₂N₅O₃S

Molecular Weight: 568.86

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	CP-547632 hydrochloride is a well-tolerated and orally-bioavailable inhibitor of the VEGFR-2 and basic FGF kinases (IC ₅₀ s: 11 nM and 9 nM) with antitumor efficacy.
Targets(IC ₅₀)	FGFR, VEGFR
In vitro	CP-547632 hydrochloride (1-1000 nM; 1 hour) inhibits VEGF-stimulated VEGFR-2 phosphorylation in a dose-dependent manner (IC ₅₀ : 6 nM).
In vivo	In DLD-1, Colo-205, and MDA-MB-231 xenografts, CP-547632 hydrochloride (p.o.; 6.25-100 mg/kg/day; for 10-24 days) causes a dose-dependent inhibition of growth. CP-547632 hydrochloride (oral; 50 mg/kg) yields plasma concentrations above 500 ng/ml for 12 hours.

Solubility Information

Solubility	DMSO: 38.33 mg/mL (67.38 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (3.52 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7579 mL	8.7895 mL	17.579 mL
5 mM	0.3516 mL	1.7579 mL	3.5158 mL
10 mM	0.1758 mL	0.879 mL	1.7579 mL
50 mM	0.0352 mL	0.1758 mL	0.3516 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Beebe JS, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. *Cancer Res.* 2003 Nov 1;63(21):7301-9.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481